Analysis of multiple transcription factor cistromes in human U-937, HL-60, CHRF-288-11, and K562 cells

Author(s):  
Trust Wellcome
Blood ◽  
2002 ◽  
Vol 99 (1) ◽  
pp. 348-356 ◽  
Author(s):  
Milind C. Mahajan ◽  
Sherman M. Weissman

Correct developmental regulation of β-like globin gene expression is achieved by preferential transcription of a gene at a given developmental stage, silencing of other β-like gene promoters, and competition among these promoters for interaction with the locus control region (LCR). Several evolutionarily conserved DNA elements in the promoters of the β-like genes and LCR have been studied in detail, and the role of their binding factors has been investigated. However, the β-globin promoter includes additional evolutionarily conserved sequences of unknown function. The present study examined the properties of a 21-base pair (bp) promoter-conserved sequence (PCS) located at positions −115 to −136 bp relative to the transcription start site of the β-globin gene. A helicaselike transcription factor (HLTF) belonging to the SWI2/SNF2 family of proteins binds to the PCS and a partly homologous sequence in the enhancer region of the LCR hypersensitive site 2 (HS2). Elevation of the level of HLTF in K562 erythroleukemic cells increases β-promoter activity in transient transfection experiments, and mutations in the PCS that remove HLTF-binding regions abolish this effect, suggesting that HLTF is an activator of β-globin transcription. Overexpression of HLTF in K562 cells does not affect the endogenous levels of γ- and ε-globin message, but it markedly activates β-globin transcription. In conclusion, this study reports a transcription factor belonging to the SWI2/SNF2 family, which preferentially activates chromosomal β-globin gene transcription and which has not previously been implicated in globin gene regulation.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2436-2436
Author(s):  
Laurie A Steiner ◽  
Yelena Maksimova ◽  
Clara Wong ◽  
Vincent Schulz ◽  
Patrick G. Gallagher

Abstract Erythrocyte membrane protein genes serve as excellent models of complex gene loci structure and function, as most encode multiple tissue-, cell-, developmental-, and stagespecific isoforms. Dynamic chromatin modifications participate in the regulatory control of many gene loci. We hypothesize that specific DNA sequences, transcription factors, and chromatin architecture (epigenetic modifications) regulate the tissue-specific expression of erythrocyte membrane protein genes. Advances in genomics technology have permitted rapid identification of DNA sequences bound by transcription factors and other DNAassociated proteins on a genome-wide scale. One technique available for mapping protein-DNA interactions in vivo couples chromatin immunoprecipitation to microarrays that contain regions of genomic DNA (ChIP-chip). We are using DNA obtained from chromatin immunoprecipitations performed with histone and erythroid transcription factor antibodies hybridized to genomic DNA microarray chips (ChIP-chip) to study the regulation of membrane protein genes in erythroid and nonerythroid cells. Chromatin immunoprecipitations (ChIP) were done in erythroid (K562) and non-erythroid (HeLa) cell lines using antibodies against H3 tri-methyl lysine 4 (H3K4me3, a marker of active chromatin) and the erythroid transcription factors GATA-1 and NF-E2. The chromatin resulting from these ChIPs was hybridized to a custom made NimbleGen high density human genomic DNA microarray (chip) focused on 15 genes critical to the erythrocyte membrane: ankyrin (ANK1), α-spectrin (SPTA1), β-spectrin (SPTB), band 3 (SLC4A1), β-adducin (ADD2), α-adducin (ADD1), γ-adducin (ADD3), ICAM-4, Erythroid Associated Membrane Protein (ERMAP), Protein 4.1 (EPB41), Protein 4.2 (EPB42), Dematin (ERPB49), β-Actin (ACTB), tropomodulin (TMOD1), and tropomyosin (TPM3). Probes for the chip were ~50bp in length with Tm ≥ 76°C, tiled every 65bp. From 50–100kb of flanking DNA was included on the chip for each locus. The Tamalpais peak calling algorithm using L1–L3 level of stringency (Genom Res16:595, 2006) was used to analyze the resulting data and identify regions of epigenetic modifications and transcription factor binding. Fourteen of 15 genes were enriched for H3K4me3 at promoter and transcriptional start sites (TSS) in K562 cells, with one gene, TMOD1, demonstrating a large peak of enrichment 5′ of the currently identified TSS, but not at the promoter. Two compact genes, β-actin and ICAM4, had H3K4me3 enrichment at the promoter and throughout gene. A total of 19 GATA-1 sites and 18 NF-E2 sites were identified. GATA-1 sites were found in 8 of 15 genes or in their flanking DNA. Three sites were in the 5′ flanking DNA, 1 site was at the promoter (~500bp from transcription start site, TSS), 12 sites were in introns, and 3 sites were in the 3′ flanking DNA. NF-E2 sites were found in 10 of 15 genes or their flanking DNA. 6 sites were in the 5′ flanking DNA, 1 site was at the promoter (~200bp from TSS), 8 sites were in introns, and 3 sites were in the 3′ flanking DNA. 18 of 19 GATA-1 sites (95%) and 13 of 18 NF-E2 sites (72%) were validated using qPCR-based quantitative ChIP. In K562 cells, 15 of 19 (79%) validated GATA-1 sites were associated with regions of chromatin enriched for H3K4me3, suggesting that ~a fifth of GATA-1 sites were in regions of inactive chromatin, consistent with a repressor function for GATA-1 at these sites. Eleven of 13 validated NF-E2 sites (85%) were associated with regions of K562 chromatin enriched for H3K4me3. In HeLa cells, the sites of GATA-1 and NF-E2 occupancy identified in K562 cells were almost never associated with H3K4me3 enrichment. GATA-1 and NF-E2 sites identified by Tamalpais and validated in K562 cells were analyzed in CD71-bright, glycophorin A-bright cultured primary erythroid cells using conventional quantitative ChIP analyses. Of the 13 NF-E2 sites identified in K562 cells, all 13 were also occupied in primary erythroid cells. ChIP-chip is a powerful tool for studying chromatin architecture and identifying transcription factor binding sites in complex genetic loci such as the erythrocyte membrane protein genes. It will be useful in constructing a comprehensive catalogue of chromatin architecture and transcription factor binding of genes expressed in erythroid cells.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3507-3507
Author(s):  
Yuanyuan Kang ◽  
Bhavita Patel ◽  
Kairong Cui ◽  
Keji Zhao ◽  
Yi Qiu ◽  
...  

Abstract Abstract 3507 T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant disease of thymocytes that mainly affects children and has very poor prognosis with high rates of relapse. A prominent feature observed in 60% of T-ALL childhood patients is the ectopic expression of a key hematopoietic transcription factor TAL1/SCL. Although several enhancers has been identified to play an important role in normal hematopoietic differentiation, the histone modification patterns and chromatin organization over the whole TAL1 locus reveled that none of them is active in T-ALL cell lines such as Jurkat and Rex cells. It remains currently unknown how TAL1 is activated in the majority of T-ALL patients lacking the TAL1 locus rearrangements. To understand the molecular mechanism underlying regulation of the TAL1 oncogene in leukemic T-cells, we employed circularized chromosome conformation capture (4C) methodology to identify new regulatory elements that activate TAL1 specifically in T-ALL leukemia. Using the TAL1 promoter 1a as the bait, we discovered that the TAL1 promoter 1a interacts with the TIL16 element (TAL1 interacting locus in chromosome 16) that is located at ∼15 Kb downstream of T-cell specific CD2BP2 gene in T-ALL cell line Jurkat, but not in erythroid progenitor K562 cells. The CD2BP2 protein is a cellular adapter protein that was originally identified as a binding partner of the T cell adhesion protein CD2 in the context of T cell signaling. The TIL16 element contains the bind sites for several transcription factors that are important for hematopoiesis such as C-Maf, Pax5, HoxA7 and USF2. The inter-chromosomal interaction between the TIL16 and the TAL1 promoter 1a was further confirmed by chromosome conformation capture (3C) assay in three TAL1 over-expressing T-ALL cell lines, Jurkat, REX and Molt4, but not in K562 cells. Recent genome wide study has correlates H3K4 mono- or dimethyl marks with distal enhancers while trimethyl H3K4 is enriched in promoters of active genes. To further test if the TIL16 acts as T-cell specific enhancer for TAL1 activation in T-ALL cells, we carried out ChIP-seq and ChIP analysis in CD4 T cells, Jurkat, and K562 cells. We found that the TIL16 element is specifically marked by H3K4me1 in Jurkat and CD4+ T-cells but not in K562 cells. The enrichment of H3K4me1 is correlated with the binding of c-Maf, a T-cell specific transcription factor. To further test whether the TIL16 element contributes to transcription activity, a DNA fragments containing the TIL16 element were cloneed into SV40 minimal promoter driven luciferase reporter and introduced into K562 and several T-ALL cell lines. Compared to the pGL3-SV40 vector that showed only minimal luciferase activity, the 1 Kb TIL element specifically activated transcription of the luciferase reporter in T-ALL cells, but not in erythroid progenitor K562 cells suggesting that the TIL16 element functions as a T-cell specific TAL1 enhancer. Thus, our data revealed a novel epigenetic mechanism by which the TAL1 oncogene is ectopically activated in T-cell leukemia. Disclosures: No relevant conflicts of interest to declare.


1992 ◽  
Vol 58 (4) ◽  
pp. 1420-1426 ◽  
Author(s):  
Andrew J. Cole ◽  
Ratan V. Bhat ◽  
Cary Patt ◽  
Paul F. Worley ◽  
Jay M. Baraban

Sign in / Sign up

Export Citation Format

Share Document